Pressmeddelande -
Read Redeye's new equity report on Alzinova AB
..............................................................
GU Ventures share news and information about the business, its companies, and alumni companies.
..............................................................
Redeye AB has revisited the Alzinova equity story with the initiation of clinical trials with ALZ-101, our vaccine candidate in Alzheimer’s, an indication with a vast unmet medical need. "Now is the time when the case could start to heat up."
Click HERE to read the full updated equity report.
Ämnen
Kategorier
Regioner
About GU Ventures AB
GU Ventures builds businesses out of groundbreaking ideas that help shape a better tomorrow and is top-ranked by UBI Global Index as one of the world's 20 leading university-run incubators. We finance and develop new innovative business ideas with connections to the University of Gothenburg, which is one of northern Europe's largest universities. Our mission is commercialize the innovations, which leads to the utilization of research and skills, renewal of the business community, job creation and sustainable growth. Our passionate team of company builders, financial experts, IP and legal talent are dedicated supporters of our companies and ensure their successes. Since our starting point in 1995, GU Ventures has developed over 200 new business ideas of which 130 are in business today and of which 14 are listed. Our portfolio consists of 70 holdings and some projects. In the latest survey, 87% of companies match the global sustainability goals set by the UN. GU Ventures is wholly owned by the Swedish state and managed by the University of Gothenburg. Feel free to read more at: www.guventures.com.
